Simulations Plus

Simulations Plus is a premier provider of modeling and simulation software and consulting services for the pharmaceutical and biotechnology industries. For over 30 years, the company has developed advanced biosimulation solutions that integrate artificial intelligence and machine learning with physiologically based pharmacokinetics, quantitative systems pharmacology, and pharmacometric modeling approaches. Their software portfolio includes GastroPlus for PBPK modeling, ADMET Predictor for property prediction, MonolixSuite for PK/PD modeling, DILIsym for liver toxicity assessment, and Thales for crystallization simulation. These tools are used by leading pharmaceutical companies, biotechnology firms, and regulatory agencies worldwide to accelerate drug discovery and development while reducing costs and improving decision-making. The company also provides comprehensive consulting services spanning early drug discovery, development, clinical operations, and commercialization support. Simulations Plus is publicly traded on NASDAQ under the ticker symbol SLP and maintains headquarters in Lancaster, California, with additional offices in Research Triangle Park, North Carolina.

Simulations Plus serves clients across the drug development continuum, from early discovery through regulatory submission and commercial launch. Their software solutions help scientists predict drug absorption, distribution, metabolism, excretion, and toxicity properties before committing to expensive clinical trials. The company's team of expert consultants works directly with clients to apply these modeling tools to specific research challenges, providing data-driven insights that inform go/no-go decisions. Simulations Plus also offers extensive training programs through their Learning Services division, including workshops, online courses, and certification programs that help researchers develop expertise in biosimulation techniques. The company's technology platform supports all major routes of drug administration and addresses critical questions in drug safety, efficacy, and formulation development.